Theriva received a $300,000 upfront payment at signing and is eligible for up to $38M in development, regulatory, and sales ...

A phase 2 trial of Lundbeck’s alpha-synuclein-targeting drug Lu AF82422 has failed to reach statistical significance in patients with multiple system atrophy (MSA), although the company says there are ...

Preclinical data demonstrate >90% reduction in human cytomegalovirus (HCMV) reactivation from latency, establishing proof-of-concept for ...

Theriva received a $300,000 upfront payment at signing and is eligible for up to $38M in development, regulatory, and sales milestones along with tiered single-digit royalties on net product sales - - ...

Accurate interpretation of cancer genomics depends on standardized disease classification, tumor characterization, and ...

Behind the AI interface, a staged system narrows tens of thousands of documents to a few, showing that visibility hinges on ...

Cybersecurity company Arctic Wolf Networks Inc. today announced that it has acquired exposure assessment startup Sevco ...

Something fundamental has shifted in how companies screen candidates, and most job seekers have no idea it's happening.

Tech marketing veteran joins BreachRx to scale the company’s go-to-market strategy and redefine how enterprises run incident ...

Looking for today's NYT Connections hints? Some help and the answers for today's game are right here to help keep your streak alive.

Safety and clinical outcomes of Phase 1 study of VCN-01 (zabilugene almadenorepvec) in refractory retinoblastoma patients to ...

NEW YORK, Feb. 19, 2026 /PRNewswire/ -- Parambil today announced the launch of its agentic AI platform for complex litigation. The release introduces four autonomous agents that actively investigate, ...